Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 30 for “"galantamine"”.
-
Galantamine's Deconstruction in the Quest of a PAM Pharmacophore
… Of the five currently FDA-approved drugs, galantamine has a unique mechanism of action. Apart from being an AChE inhibitor, galantamine can effectively potentiate (positive allosteric modulator) the effect of agonists at nAChRs at concentrations lower than those required for its action as …
-
Adverse Outcomes Associated with Individual Cholinesterase Inhibitors in Older Adults with Dementia
… was the receipt of individual ChEIs (donepezil, galantamine, or rivastigmine). The conceptual framework of the Andersen Behavioral model was used to select the predisposing, enabling, and need factors. Multivariable Cox proportional hazards regression with Propensity scores (PS) as covariates and …
-
Characterization of the Hippocampal Acetylcholine System in a Rodent Model of Fetal Alcohol Syndrome
… solution (PD 32) and the effects of an acute galantamine (2.0 mg/kg; PD 34) injection on acetylcholine release were measured. Experiment 3 tested whether chronic administration of galantamine (2.0 mg/kg; PD 11-30), an acetylcholinesterase inhibitor, could attenuate alcohol-induced learning …
-
Age-Related Differences in In-vitro Sensitivity to Inhibition of Human Red Blood Cell Acetylcholinesterase and Plasma Butyrylcholinesterase by the Cholinesterase Inhibitors Physostigmine (PHYS), Pyridostigmine (PYR), Donepezil (DON) and Galantamine (GAL)
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder, characterized clinically by a progressive loss of memory, cognitive function, ability to care for oneself and psychiatric symptoms. First-line agents for the treatment of AD are ChE inhibitors (DON, GAL), whose modest …
-
Investigating the influence of Age on Pharmacokinetic and Pharmacodynamic characteristics of Gold standard Alzheimer's Disease drugs in the lister - Hooded Rat.
… PK/PD properties of AD drugs Aricept, Tacrine, Galantamine, and Memantine, were investigated in an aged Lister-hooded rat model. Intravenous and oral 6h blood-sampling profiles in old (30-months) and young (7-months) rats revealed similar PK changes to humans with significant increase in Cmax of …
-
Functional Changes to the Modulation of alpha4beta2* Nicotinic Acetylcholine Receptors During Postnatal Maturation
… by nicotine, allopregnanolone (ALLO) and galantamine. nAChR desensitization by nicotine was greater in young mice and this result was driven by an effect of postnatal age in males only. In contrast, ALLO inhibited nAChR function to a similar degree at each age. Galantamine potentiated …
-
Effects of Pharmacological Manipulation of the Serotonergic/Cholinergic Systems on Sleep Structure in Two 5-HT1A Genotypes: Implications for a Model of Depression
… non-consecutive nights. Participants were given galantamine (an anti-acetylcholinesterase), buspirone (a serotonergic agonist), both drugs together, or placebos before sleeping. Buspirone suppressed tonic REM: there was a significant increase in REM latency (p<0.001). Galantamine increased tonic …
-
Concomitant Use of Atypical Antipsychotics and Cholinesterase Inhibitors Among Older Adults with Dementia
… inhibitors (AChEIs), donepezil, rivastigmine, or galantamine; (2) evaluate the risk of falls and fractures due to the concomitant use of AChEIs and atypical antipsychotics (classified as high versus low anticholinergic) among older adults with dementia; and (3) evaluate the risk of mortality due …
-
Long Term Outcome and Prediction Models of Cognition, Activities of Daily Living and Nursing Home Placement in Alzheimer’s Disease with Cholinesterase Inhibitor Treatment
… patients treated with donepezil, rivastigmine or galantamine III. 790 patients treated with donepezil, rivastigmine or galantamine IV. 880 patients treated with donepezil, rivastigmine or galantamine Results I. Regression models predicted 3-year cognitive outcome in ChEI-treated patients with high …
-
ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR REGULATION IN EXPERIMENTAL NEURODEGENERATIVE DISEASE
… resulting in upregulation. In a second study, galantamine, a medication used in the treatment of AD, was administered subchronically following experimental TBI to determine if treatment could facilitate cognitive recovery and affect nAChR expression. Interestingly, the results indicate TBI …
-
Cholinesterase Inhibitors: A population-based assessment of resource utilization for patients with Alzheimer's dementia in Ontario
… cholinesterase inhibitors (ChEIs) – donepezil, galantamine and rivastigmine – have been approved for the treatment of dementia and are covered under Ontario’s formulary plan, but there has been little research regarding their economic impact. Methods: The purpose of this study was to describe …
-
Influence of a Nicotinic Treatment on Auditory Sensory Processing in Schizophrenia
… with selective α7 nAChR agonist properties and galantamine, a nAChR positive allosteric modulator (PAM), which was posited to augment α7 nAChR signalling. Auditory sensory processing was examined with ERP paradigms assessing two functions commonly impaired in SCZ; (a) the ability to inhibit …
-
A cost-benefit analysis of Alzheimer’s disease treatment options
… six drugs: aducanumab, donepezil, rivastigmine, galantamine, memantine, and memantine-donepezil combination. Aducanumab is the only disease-modifying drug to receive FDA approval, but its efficacy is marred in controversy and it lacks cost-effectiveness. The remaining five drugs all have similar …
-
Εκτίμηση ασφάλειας και αποτελεσματικότητας των φαρμάκων που χρησιμοποιούνται στην αντιμετώπιση της άνοιας: μετα-ανάλυση
… criteria for AD (10 trials for donepezil, 3 for galantamine, 4 for rivastigmine and 5 for memantine). Data suggest rather modest benefit for ChEIs and memantine in cognition (Weighted Mean Difference-WMD for ADAS-cog -2.56, 95% CI -3.12, -2.01). Benefits have been observed in global function …
-
DEVELOPMENT OF HPLC METHODS FOR PHARMACEUTICALLY RELEVANT MOLECULES; METHOD TRANSFER TO UPLC: COMPARING METHODS STATISTICALLY FOR EQUIVALENCE
… to UPLC. An existing HPLC method for analysis of Galantamine hydrobromide was converted to UPLC and validated according to ICH guidelines. A series of statistical evaluations on the validation data were performed to prove the equivalency between the original HPLC and the new UPLC method. This …
-
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitor use
… over, and either initiated the use of donepezil, galantamine, oral rivastigmine, or transdermal rivastigmine (defined as no previous dispensation of AChEI recorded in NPDUIS in 365 days prior). The outcome of a hospitalization for malignant arrhythmia was identified by ICD-10-CA codes I47.2 and …
-
Long-term treatment response, predictors and biochemical markers in Alzheimer’s disease.
… (ChEIs) (tacrine, donepezil, rivastigmine, galantamine) were introduced as treatments for AD. Multiple short-term randomised clinical trials of ChEI treatment show beneficial effects on cognition, global functioning and activities of daily living in AD. Whether the effects of long-term ChEI …
-
Yellow field pea and hemp protein hydrolysates as tools to enhance the health benefits and sensory quality of meat alternatives
… (AChE) inhibitory activity than galantamine (AChE inhibitor drug), however, those made with pea protein hydrolysates showed better inhibition than the MAs that contained hemp hydrolysates. Results from this study indicate the potential use of plant-based protein hydrolysates to …
-
Identifying Intervention Opportunities in the Continuum of Cognitive Impairment Among Persons Aging with HIV
… dementia medications (donepezil, rivastigmine, galantamine, memantine) among individuals who received a dementia diagnosis via Poisson regression models with robust variance. In Aim 3, the proportion of cognitive impairment in men with HIV potentially attributable to current smoking was …
-
Changes in cerebral glucose metabolism in patients with Parkinson’s disease with dementia after cholinesterase inhibitor therapy
… Patients were treated with either donepezil or galantamine. End point was when patients were treated for at least 3 months and when the patient or family members reported improved cognition. 18F-FDG PET scan was done before initiation of treatment and after completion drug trial. SPM images were …
Page 1 of 2